Select Publications
Journal articles
2018, 'Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.', JOURNAL OF CLINICAL ONCOLOGY, 36, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e16206
,2018, 'Patients’ preferences for 3 months versus 6 months of adjuvant chemotherapy (ACT) for colon cancer in the SCOT trial: what survival benefits make longer chemotherapy worthwhile?', Journal of Clinical Oncology, 36, pp. 3602 - 3602, http://dx.doi.org/10.1200/jco.2018.36.15_suppl.3602
,2018, 'Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma', Gastric Cancer, 21, pp. 473 - 480, http://dx.doi.org/10.1007/s10120-017-0754-1
,2018, 'The PiGeOn project: Protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer', BMC Cancer, 18, pp. 389, http://dx.doi.org/10.1186/s12885-018-4366-x
,2018, 'Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer', British Journal of Cancer, 118, pp. 947 - 954, http://dx.doi.org/10.1038/s41416-018-0004-2
,2018, 'Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy', British Journal of Cancer, 118, pp. 1084 - 1088, http://dx.doi.org/10.1038/s41416-018-0005-1
,2018, 'Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy', Muscle and Nerve, 57, pp. 615 - 621, http://dx.doi.org/10.1002/mus.25968
,2018, 'Oxaliplatin induces muscle loss and muscle-specific molecular changes in Mice', Muscle and Nerve, 57, pp. 650 - 658, http://dx.doi.org/10.1002/mus.25966
,2018, 'Barriers and facilitators of exercise experienced by cancer survivors: a mixed methods systematic review', Supportive Care in Cancer, 26, pp. 685 - 700, http://dx.doi.org/10.1007/s00520-017-3964-5
,2018, 'Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease', The Lancet Oncology, 19, pp. e151 - e160, http://dx.doi.org/10.1016/S1470-2045(18)30098-6
,2018, 'Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study', Gut, 68, pp. 663 - 671, http://dx.doi.org/10.1136/gutjnl-2017-315852
,2018, 'Biliary Stenting in Patients with Pancreatic Cancer: Results from a Population-Based Cohort Study', Pancreas, 47, pp. 80 - 86, http://dx.doi.org/10.1097/MPA.0000000000000960
,2018, '5. Neurophysiological dysfunction in chemotherapy-treated patients: Comparison of different platinum analogues', Clinical Neurophysiology, 129, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2017.12.018
,2018, '517 - World-First Identification of Circulating Pancreatic Stellate Cells in Metastatic Pancreatic Cancer', Gastroenterology, 154, pp. S - 114, http://dx.doi.org/10.1016/s0016-5085(18)30816-3
,2017, 'Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey', Supportive Care in Cancer, 25, pp. 3485 - 3493, http://dx.doi.org/10.1007/s00520-017-3772-y
,2017, 'Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty', Expert Review of Anticancer Therapy, 17, pp. 951 - 964, http://dx.doi.org/10.1080/14737140.2017.1369882
,2017, 'Communication challenges experienced by migrants with cancer: A comparison of migrant and English-speaking Australian-born cancer patients', Health Expectations, 20, pp. 886 - 895, http://dx.doi.org/10.1111/hex.12529
,2017, 'Information needs of the Chinese community affected by cancer: A systematic review', Psycho-Oncology, 26, pp. 1433 - 1443, http://dx.doi.org/10.1002/pon.4347
,2017, 'Systemic treatment in advanced biliary cancers: A multicenter Australian analysis and review', Asia-Pacific Journal of Clinical Oncology, 13, pp. e291 - e297, http://dx.doi.org/10.1111/ajco.12638
,2017, 'Perspectives of oncology nurses and oncologists regarding barriers to working with patients from a minority background: systemic issues and working with interpreters.', European Journal of Cancer Care, 27, pp. e12758, http://dx.doi.org/10.1111/ecc.12758
,2017, 'COnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMMPACT)', ANNALS OF ONCOLOGY, 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001259&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with imatinib as an adjuvant: Final results of the EORTC STBSG, AGITG, UNICANCER, FSG, ISG, and GEIS randomized trial', ANNALS OF ONCOLOGY, 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324005130&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD)', ANNALS OF ONCOLOGY, 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001135&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer', Clinical Neurophysiology, 128, pp. 1166 - 1175, http://dx.doi.org/10.1016/j.clinph.2017.04.009
,2017, 'Circulating pancreatic stellate (stromal) cells in pancreatic cancer-a fertile area for novel research', Carcinogenesis, 38, pp. 588 - 591, http://dx.doi.org/10.1093/carcin/bgx030
,2017, 'Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer', Annals of oncology : official journal of the European Society for Medical Oncology, 28, pp. iii142 - iii144, http://dx.doi.org/10.1093/annonc/mdx262.016
,2017, 'Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcoma', International Journal of Molecular Sciences, 18, pp. 1159, http://dx.doi.org/10.3390/ijms18061159
,2017, 'Integrate II: A randomised phase 3 double-blind placebo-controlled study of regorafenib in refractory advanced gastro-oesophageal cancer (AGOC)—An international study organized by the Australasian Gastrointestinal Trials Group (AGITG).', Journal of Clinical Oncology, 35, pp. TPS4136 - TPS4136, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.tps4136
,2017, 'Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.', Journal of Clinical Oncology, 35, pp. 4120 - 4120, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4120
,2017, 'Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).', Journal of Clinical Oncology, 35, pp. 4109 - 4109, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4109
,2017, 'Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.', Journal of Clinical Oncology, 35, pp. 4101 - 4101, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4101
,2017, 'The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).', Journal of Clinical Oncology, 35, pp. 3521 - 3521, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.3521
,2017, 'Systemic therapy in younger and elderly patients with advanced biliary cancer: Sub-analysis of ABC-02 and twelve other prospective trials', BMC Cancer, 17, pp. 262, http://dx.doi.org/10.1186/s12885-017-3266-9
,2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
,2017, 'Anxiety, depression and quality of life in people with pancreatic cancer and their carers', Pancreatology, 17, pp. 321 - 327, http://dx.doi.org/10.1016/j.pan.2017.01.008
,2017, 'Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy', European Journal of Cancer, 73, pp. 22 - 29, http://dx.doi.org/10.1016/j.ejca.2016.12.006
,2017, 'New molecular and immunotherapeutic approaches in biliary cancer', ESMO Open, 2, pp. e000152, http://dx.doi.org/10.1136/esmoopen-2016-000152
,2017, 'Communicating with patients from minority backgrounds: Individual challenges experienced by oncology health professionals', European Journal of Oncology Nursing, 26, pp. 83 - 90, http://dx.doi.org/10.1016/j.ejon.2016.12.001
,2017, 'Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).', JOURNAL OF CLINICAL ONCOLOGY, 35, http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.227
,2017, 'The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis', PLoS ONE, 12, pp. e0172307, http://dx.doi.org/10.1371/journal.pone.0172307
,2017, 'Assessing the need for an educational intervention for primary care practitioners on HPV-related oropharyngeal cancer', University of Toronto Medical Journal, 94, pp. 17 - 21
,2017, 'Characterisation of immune and neuroinflammatory changes associated with chemotherapy-induced peripheral neuropathy', PLoS ONE, 12, pp. e0170814, http://dx.doi.org/10.1371/journal.pone.0170814
,2017, 'MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity', Oncotarget, 8, pp. 9216 - 9229, http://dx.doi.org/10.18632/oncotarget.13985
,2017, 'Rituximab to treat gemcitabine-induced hemolytic–uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review', Cancer Chemotherapy and Pharmacology, 79, http://dx.doi.org/10.1007/s00280-016-3123-6
,2017, 'Targeting the HGF/c-MET pathway: Stromal remodelling in pancreatic cancer', Oncotarget, 8, pp. 76722 - 76739, http://dx.doi.org/10.18632/oncotarget.20822
,2017, 'The role of chemotherapy in gastric cancer-related microangiopathic haemolytic anaemia', Journal of Gastrointestinal Oncology, 8, pp. E10 - E15, http://dx.doi.org/10.21037/jgo.2016.11.14
,2017, 'Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study', Pancreas, 46, pp. 203 - 208, http://dx.doi.org/10.1097/MPA.0000000000000742
,2017, 'Neutrophils Predicting Tumor Local Control After Chemoradiation Therapy in Locally Advanced Pancreatic Carcinoma in the LAP 07 Trial', International Journal of Radiation Oncology*Biology*Physics, 99, pp. S88 - S89, http://dx.doi.org/10.1016/j.ijrobp.2017.06.213
,2016, 'Factors associated with quality of care for patients with pancreatic cancer in Australia', Medical Journal of Australia, 205, pp. 459 - 465, http://dx.doi.org/10.5694/mja16.00567
,2016, 'Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines', Anticancer research, 36, pp. 5765 - 5772, http://dx.doi.org/10.21873/anticanres.11160
,